You are here

  • Home
  • Archive
  • Volume 21, Issue 6
  • The Preparation of Human Papillomavirus Type 58 Vaccine and Exploring Its Biological Activity and Immunogenicity In Vitro

Article Text

Article menu
Download PDFPDF
Basic Science
The Preparation of Human Papillomavirus Type 58 Vaccine and Exploring Its Biological Activity and Immunogenicity In Vitro
  1. Dongrui Deng, MD,
  2. Shujie Liao, MD,
  3. Xiangyang Bai, MD,
  4. Wei Wang, MD,
  5. Ni Sima, MD,
  6. Qian Xu, MD,
  7. Tao Zhu, MD,
  8. Gang Xu, MD,
  9. Jianfeng Zhou, MD,
  10. Shixuan Wang, MD,
  11. Li Meng, MD and
  12. Ding Ma, MD
  1. Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
  1. Address correspondence and reprint requests to Ding Ma, MD, Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, People's Republic of China. E-mail: dma{at}tjh.tjmu.edu.cn or Li Meng, MD, Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, People's Republic of China. E-mail: mengli19{at}hotmail.com.

Abstract

Objectives: Human papillomavirus (HPV) type 58 is the second most prevalent virus infection among Chinese women. To develop an HPV58 vaccine that combines both prophylactic and therapeutic functions, we generate a chimeric virus-like particle (cVLP).

Methods: The cVLPs contain both whole length L1 and parts of E7 peptides either from E7 amino acids (aa) 50 to aa72 or from E7 aa4 to aa12. The HPV58 L1-E7aa50-72 and L1-E7aa4-12 fusion proteins were revealed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and confirmed by Western blot (Supplementary Digital Content 1, http://links.lww.com/IGC/A40, which shows alignment of the protein sequence between HPV58 L1-E7aa50-72/4-12 and standard sequence). Protein folding and location of cVLPs were identified by transmission electron microscope. The immunogenicity of the fusion protein was tested by enzyme-linked immunospot assay.

Results Transmission electron microscope showed that the fusion protein formed cVLPs by self-assembly and the majority of particles located in the nucleus of the sf-9 insect cells. The cVLPs displayed a strong ability to agglutinate erythrocytes, which is distinguished from the parental VLPs. In addition, the purified HPV58 L1-E7aa50-72 or L1-E7aa4-12 fusion protein induced significant numbers of interferon γ-expressing E7aa50-72- or E7aa4-12-specific CD8+ T cells.

Discussion Our results indicate that the insertion of the E7aa50-72 or E7aa4-12 peptides behind L1 did not disrupt the assembly of cVLPs and provided potent immunogenicity and bioactivity, which created a powerful basis for further preparations of HPV58 vaccines with prophylactic and therapeutic effects for the treatment of HPV58-related diseases including cervical cancer.

  • Cervical cancer
  • Human papillomavirus type 58
  • Baculovirus expression system
  • Vaccine
  • Chimeric virus-like particles

https://doi.org/10.1097/IGC.0b013e31821dc8e5

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Drs Deng and Liao contributed equally to this work.

    • This work was supported by grants from the National Natural Science Foundation of China (30672227, 30600667, 30901586, 30973205) Major Innovation Medicine program (2009ZX09103-738, 2009ZX09103-739) and the "973" Program of China (2009CB521800).

    • The authors have no conflicts of interest to report.

    • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal's Web site (www.ijgc.com).